119 related articles for article (PubMed ID: 19514366)
1. [Ovarian carcinoma: certain characteristics of evolution, advancement and diagnosis].
Prokopenko PG; Terent'ev AA
Vopr Onkol; 2009; 55(2):143-50. PubMed ID: 19514366
[No Abstract] [Full Text] [Related]
2. [Ovarian cancers and CA 125 in 2006].
Lambaudie E; Collinet P; Vinatier D
Gynecol Obstet Fertil; 2006 Mar; 34(3):254-7. PubMed ID: 16529967
[TBL] [Abstract][Full Text] [Related]
3. [CA 125 in epithelial ovarian cancer].
Mogensen O
Ugeskr Laeger; 1998 May; 160(22):3236. PubMed ID: 9621807
[No Abstract] [Full Text] [Related]
4. [Tumor markers and ovarian cancer].
Trifonov I; Todorova M
Akush Ginekol (Sofiia); 2002; 41 Suppl 1():7-11. PubMed ID: 12412346
[No Abstract] [Full Text] [Related]
5. Autoimmune hemolytic anemia associated with ovarian cancer.
Morris PG; Swords R; Sukor S; Fortune A; O'Donnell DM; Conneally E
J Clin Oncol; 2008 Oct; 26(30):4993-5. PubMed ID: 18809611
[No Abstract] [Full Text] [Related]
6. A case of tuberculous peritonitis with elevated CA 125.
Cakir M; Dilber E; Yariş N; Mungan I; Okten A
Turk J Pediatr; 2005; 47(1):100-2. PubMed ID: 15884642
[No Abstract] [Full Text] [Related]
7. [Tumour markers in epithelial ovarian cancer].
Sparholt MH; Høgdall E; Høgdall CK
Ugeskr Laeger; 2009 Nov; 171(48):3505-9. PubMed ID: 19944049
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA as a prognostic factor.
Rafii A; Querleu D
Am J Obstet Gynecol; 2006 Jul; 195(1):335; author reply 336. PubMed ID: 16579938
[No Abstract] [Full Text] [Related]
9. [CA-125 as response parameter in ovarian carcinoma].
Zirpel I; Illiger HJ
Strahlenther Onkol; 2000 Apr; 176(4):200. PubMed ID: 10841742
[No Abstract] [Full Text] [Related]
10. Letter commenting on the article "CA 125 expression pattern, prognosis and correlation with serum CA 125 in ovarian tumor patients" (104:508-515) by Hogdall, et al and on the Editorial "CA 125: megadaltons of novel opportunities" (104:505-507).
van Altena AM; de Hullu JA; Massuger LF
Gynecol Oncol; 2007 Nov; 107(2):355-6. PubMed ID: 17707896
[No Abstract] [Full Text] [Related]
11. Monitoring ovarian cancer: CA125 trial stirs controversy.
Chitale R
J Natl Cancer Inst; 2009 Sep; 101(18):1233-5. PubMed ID: 19738165
[No Abstract] [Full Text] [Related]
12. Clinical decision making using ovarian cancer risk assessment.
Stany MP; Maxwell GL; Rose GS
AJR Am J Roentgenol; 2010 Feb; 194(2):337-42. PubMed ID: 20093593
[TBL] [Abstract][Full Text] [Related]
13. CA-125 and early ovarian cancer: does this help the clinician or further muddy the water?
McGuire WP
J Clin Oncol; 2005 Sep; 23(25):5862-4. PubMed ID: 16087955
[No Abstract] [Full Text] [Related]
14. [Key problems to diagnosis and treatment of epithelial ovarian cancer].
Shen K; Lang JH
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):65-8. PubMed ID: 12833894
[No Abstract] [Full Text] [Related]
15. The myth of measurable disease in ovarian cancer.
Markman M
J Clin Oncol; 2003 Aug; 21(16):3013-5. PubMed ID: 12915591
[No Abstract] [Full Text] [Related]
16. A new model of ovarian carcinogenesis may influence early detection strategies.
Burger RA
Am J Obstet Gynecol; 2008 Apr; 198(4):349-50. PubMed ID: 18395029
[No Abstract] [Full Text] [Related]
17. StatBite: Ovarian cancer: risk of recurrence by stage of diagnosis.
J Natl Cancer Inst; 2009 Sep; 101(18):1234. PubMed ID: 19738164
[No Abstract] [Full Text] [Related]
18. A review and an update on the screening of epithelial ovarian cancer.
Reynolds EA; Moller KA
Curr Probl Cancer; 2006; 30(5):203-32. PubMed ID: 16996383
[No Abstract] [Full Text] [Related]
19. The myth of measurable disease in ovarian cancer: revisited.
Markman M
Cancer Invest; 2009 Jan; 27(1):11-2. PubMed ID: 19160094
[TBL] [Abstract][Full Text] [Related]
20. Cancer patients' anxiety.
Sundar S; Symonds P
Lancet; 2003 May; 361(9370):1746-7. PubMed ID: 12767769
[No Abstract] [Full Text] [Related]
[Next] [New Search]
